Results 131 to 140 of about 390,868 (309)
Background: The definitive treatment for end-stage heart failure (ESHF) due to amyloid cardiomyopathy (ACM) is an orthotopic heart transplant (OHT).
Pankaj Garg, MBBS +12 more
doaj +1 more source
Novel Vascular‐Adaptive Liquid Metal Microspheres Enable Visualized Arterial Embolization Therapy
We present drug‐loaded liquid metal microspheres (X‐MEN) as a novel agent for image‐guided arterial embolization. With inherent radiopacity and superior deformability, X‐MEN enables real‐time monitoring and conforms tightly to irregular vessels. This approach ensures precise, long‐lasting embolization without recanalization, addressing critical ...
Chenyu Shen +14 more
wiley +1 more source
ABSTRACT Extracellular vesicles (EVs) are nanoscale mediators of intercellular communication with diverse molecular cargoes that reflect their cell of origin. Advances in isolation, detection, and single‐particle analytics have revealed increasing molecular and functional heterogeneity, while exposing limitations in how EV identity and activity are ...
David J. Lundy +8 more
wiley +1 more source
Background/Objectives: Sodium glucose co-transporter 2 inhibitors (SGLT2is) improve outcomes in heart failure; however, data in left ventricular non-compaction cardiomyopathy (LVNC) patients are limited.
Andraž Cerar +8 more
doaj +1 more source
ABSTRACT Advancements in tissue engineering have revolutionized therapeutic paradigms for diabetic tissue defects; however, the lack of applicable scaffold containing various bioactive substance aggregates remained a critical bottleneck hindering satisfactory repair effect.
Tao Wang +8 more
wiley +1 more source
Successful heart transplantation in a patient with Ivemark syndrome combined with situs inversus, single atrium and ventricle after total cavo-pulmonary connection [PDF]
Heart transplantation represents a valuable therapeutical option for patients with congenital heart disease and end-stage heart failure. We report the case of a young adult patient with a situs inversus and additional complex congenital malformations of ...
Althaus, Ulrich +3 more
core
Heterotopic heart transplantation [PDF]
Richard A. Kerensky +3 more
openaire +2 more sources
Producing MSCs on rigid culture substrates induces a scar‐making phenotype, jeapordizing therapeutic success. ‘Tissue‐soft’ surfaces prevent MSC fibrogenesis and preserve regenerative traits. An epigenetic network, driven by HOXA11 and SALL1, maintains ‘soft memory’ by keeping chromatin open in relaxed MSCs, promoting anti‐fibrotic programs.
Fereshteh Sadat Younesi +7 more
wiley +1 more source
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
A dual‐network bFGF@CB‐gel integrates: i) ChSMA scaffold (mechanical support/BMSCs delivery); ii) BC carrier (sustained bFGF release via EGFL/Itga2b and COMP/PI3K/AKT for adhesion/osteogenesis); iii) bFGF/PI3K/AKT/eNOS for angiogenesis. This rational, synergistic design addresses CSD bone regeneration challenges.
Yunze Feng +12 more
wiley +1 more source

